Liver Metastasis Treatment Market By Treatment Type (Systemic Therapy [Chemotherapy, Targeted Therapy, Immunotherapy], Surgical Resection, Ablation Therapy [Radiofrequency Ablation, Microwave Ablation, Cryoablation], Embolization Therapy [Transarterial Chemoembolization, Radioembolization], Radiation Therapy, Hepatic Artery Infusion, Histotripsy, Liver Transplantation); By Primary Cancer Type (Colorectal Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, Melanoma, Neuroendocrine Tumours, Other Cancers); By End User (Hospitals, Cancer Treatment Centers, Specialty Oncology Clinics, Ambulatory Surgical Centers, Academic and Research Institutions); By Geography, Segment Revenue Estimation, Forecast: 2026–2032

Liver Metastasis Treatment Market: Systemic Oncology and Liver-Directed Intervention Reshape Multimodal Care

The Global Liver Metastasis Treatment Market was valued at approximately USD 2.60 billion in 2025 and is projected to reach USD 4.42 billion by 2032, expanding at a CAGR of 7.9% during 2026–2032, according to internal projections by Strategic Market Research.

 

Liver metastasis treatment combines systemic and liver-directed approaches. Systemic options include chemotherapy, targeted therapies (EGFR, VEGF, HER2, BRAF/MEK), and immunotherapy (PD-1/PD-L1, CTLA-4 inhibitors), chosen based on the primary tumor type. Local treatments include surgery, thermal ablation, radioembolization (Y-90), hepatic artery infusion, and stereotactic radiation to control liver-dominant disease. Colorectal cancer offers the most established curative pathway, while breast, pancreatic, and neuroendocrine cancers follow specific protocols. Overall treatment selection depends on tumor origin, molecular profile, disease spread, and access to specialized liver centers.

 

Systemic therapy accounted for 50.0% of the market in 2025, generating USD 1.30 billion, and is expected to reach USD 2.34 billion by 2032 at an 8.8% CAGR, increasing its share to 53.0%. Chemotherapy is gradually losing share, falling from 22.0% (USD 0.57 billion) in 2025 to 18.0% (USD 0.80 billion) by 2032 as targeted and biomarker-driven therapies expand. The U.S. sees an estimated 140,000 secondary liver cancer cases annually, with about 5.14% of new cancer patients presenting with liver metastases at diagnosis. Colorectal, breast, pancreatic, and lung cancers are the main sources, with liver involvement seen in up to 70% of colorectal, 50% of metastatic breast, and around 40% of pancreatic cancer cases, highlighting sustained demand for systemic treatment options.

 

Colorectal Cancer Anchors the Largest Structured Treatment Pathway

Colorectal cancer represents the most established clinical and commercial segment. The World Health Organization estimates that approximately 2.0 million new colorectal cancer cases and 918,000 associated deaths occurred worldwide in 2024. The National Cancer Institute’s SEER program projects 158,850 new U.S. cases and 55,230 deaths in 2026, while NICE estimates that 30% to 50% of people with colorectal cancer either present with liver metastases or develop them during their disease course.

Colorectal cancer accounted for 40.0% of market revenue and USD 1.04 billion in 2025. It is projected to reach USD 1.72 billion by 2032 at a 7.5% CAGR while retaining the largest share at 39.0%. Its position reflects the frequency of hepatic spread and the availability of established systemic, surgical, ablative and arterial treatment pathways.

Breast cancer remains the largest segment, growing from USD 0.39 billion in 2025 to USD 0.71 billion by 2032 (8.9% CAGR), driven by screening and strong uptake of targeted therapies such as Roche’s HER2 drugs and CDK4/6 inhibitors from Novartis and Eli Lilly. Lung cancer follows, rising from USD 0.31 billion to USD 0.57 billion (9.1% CAGR), supported by widespread use of immunotherapies like Merck’s Keytruda, BMS’s Opdivo, and AstraZeneca’s Tagrisso.

Pancreatic cancer grows more slowly from USD 0.23 billion to USD 0.40 billion (7.9% CAGR) due to late diagnosis, though KRAS-targeted and combination therapies are improving outcomes. Melanoma increases from USD 0.16 billion to USD 0.31 billion (10.3% CAGR), driven by checkpoint inhibitors from Merck and BMS. Neuroendocrine tumours rise from USD 0.21 billion to USD 0.40 billion (9.7% CAGR), supported by Novartis’ Lutathera and radioligand therapies. Other cancers grow modestly from USD 0.26 billion to USD 0.31 billion (2.5% CAGR) due to limited innovation.

 

Resectability Conversion Creates the Highest-Value Treatment Episodes

Complete liver resection remains the principal curative-intent treatment for technically operable colorectal liver metastases. The National Cancer Institute reports five-year survival of approximately 25% to 40% following negative-margin resection in selected patients and a five-year cure rate above 20% after resection of selected solitary or combined metastases.

Surgical resection accounted for 18.0% of the market and USD 0.47 billion in 2025. It is projected to reach USD 0.71 billion by 2032 at a CAGR of 6.1%, although its share is expected to decline to 16.0% as systemic and minimally invasive treatments grow faster. Revenue extends beyond the operation to imaging, volumetric planning, pathology, hospitalization, postoperative surveillance and perioperative therapy.

Multiple bilobar lesions, vascular involvement, insufficient functional liver reserve or uncontrolled extrahepatic disease can prevent immediate surgery. Conversion chemotherapy, portal-vein embolization, staged hepatectomy, ALPPS, parenchymal-sparing resection, ablation-assisted surgery and hepatic artery infusion can move selected patients into a combined drug, interventional and surgical pathway. The National Cancer Institute states that patients whose initially unresectable disease becomes operable after chemotherapy can achieve five-year survival comparable to patients with resectable disease at presentation, although no consensus conversion regimen has been established.

Hospitals remained the largest end-user group in 2025, accounting for 46.0% and USD 1.20 billion. Their revenue is projected to reach USD 1.90 billion by 2032 at a 6.8% CAGR, while their share declines to 43.0% as specialist cancer centers gain a larger role in multidisciplinary treatment.

 

Thermal Ablation Expands Local Treatment for Smaller Lesions

Radiofrequency and microwave ablation provide local treatment for patients with limited liver disease who cannot undergo major surgery or require ablation alongside resection. The National Cancer Institute identifies radiofrequency ablation as an option for unresectable tumors and patients unsuitable for liver resection, citing approximately 2% major morbidity and mortality below 1%.

Ablation therapy represented 12.0% of the market and USD 0.31 billion in 2025. It is projected to reach USD 0.57 billion by 2032, increasing its share to 13.0% at a 9.1% CAGR. Radiofrequency ablation should grow from USD 0.16 billion to USD 0.24 billion at 6.5%, while its share declines from 6.0% to 5.5%. Microwave ablation is expected to rise from USD 0.10 billion and 4.0% to USD 0.24 billion and 5.5% at a 12.9% CAGR. Cryoablation is projected to increase from USD 0.05 billion to USD 0.09 billion at 7.9%, maintaining a 2.0% share.

Growth is linked to generators, single-use probes, image guidance, fusion software and margin-verification systems. Ablation also preserves liver tissue for future intervention and supports selected outpatient procedures. Ambulatory surgical centers are consequently the fastest-growing end-user segment, rising from USD 0.13 billion and 5.0% in 2025 to USD 0.27 billion and 6.0% by 2032 at a 10.7% CAGR.

 

Arterial Therapies Address Liver-Dominant Unresectable Disease

Selective internal radiation therapy and transarterial chemoembolization exploit the hepatic arterial supply to deliver radiation, chemotherapy or embolic material close to tumors. Embolization therapy accounted for 11.0% of the market and USD 0.29 billion in 2025 and is projected to reach USD 0.44 billion by 2032 at a 6.4% CAGR, while its share declines to 10.0%.

Transarterial chemoembolization represented USD 0.16 billion and 6.0% of the market in 2025. It is forecast to reach USD 0.22 billion and 5.0% by 2032 at a 5.1% CAGR. Radioembolization generated USD 0.13 billion and held 5.0% in 2025 and is projected to reach USD 0.22 billion by 2032 at 7.9%, maintaining its share.

Regulatory approvals vary by therapy and indication. SIR-Spheres is FDA-approved for unresectable colorectal liver metastases when used with intra-arterial chemotherapy, while TheraSphere is approved for unresectable hepatocellular carcinoma rather than colorectal metastases. In Europe, NICE allows selective internal radiation therapy for colorectal liver metastases under strict patient-selection and monitoring rules, supporting use mainly in specialist hospital centers with advanced imaging and interventional capabilities.

Hepatic artery infusion (HAI) pumps deliver high-dose chemotherapy directly to the liver and are typically combined with systemic therapy. A National Cancer Institute–cited study showed improved outcomes with HAI plus systemic treatment, including 57% vs 42% two-year progression-free survival and 86% vs 72% two-year overall survival compared to systemic therapy alone. In the U.S., Medicare provides coverage for HAI in selected clinical settings, supporting its use in specialized cancer centers.

Cancer treatment centers accounted for 30.0% of the market and USD 0.78 billion in 2025. Their revenue is projected to reach USD 1.46 billion by 2032, increasing their share to 33.0% at a 9.4% CAGR as complex systemic and liver-directed programs become concentrated in dedicated oncology facilities.

 

Molecular Stratification Reshapes Systemic-Therapy Revenue

Systemic treatment remains the largest recurring revenue pathway because most patients require control of visible liver lesions and disease elsewhere. Targeted therapy represented 17.0% of the market and USD 0.44 billion in 2025 and is projected to reach USD 0.84 billion by 2032, increasing its share to 19.0% at a 9.6% CAGR. Immunotherapy is the fastest-growing treatment subsegment, rising from USD 0.29 billion and 11.0% to USD 0.71 billion and 16.0% at a 13.8% CAGR.

In metastatic colorectal cancer, RAS, BRAF, mismatch-repair, microsatellite-instability and HER2 testing determine eligibility for targeted or immune-based regimens. The FDA approved sotorasib with panitumumab in January 2025 for previously treated KRAS G12C-mutated disease and nivolumab with ipilimumab in April 2025 for unresectable or metastatic MSI-H or dMMR colorectal cancer.

In February 2026, the FDA approved encorafenib combined with cetuximab and fluorouracil-based chemotherapy for BRAF V600E-mutated metastatic colorectal cancer. In the BREAKWATER study, this regimen improved median overall survival to 30.3 months versus 15.1 months with standard therapy, and progression-free survival to 12.8 months versus 7.1 months.

While not limited to liver metastases, these stronger response rates can reduce liver tumor burden and help some patients become eligible for surgery or ablation. This is also supporting growth in specialty oncology clinics, which are projected to rise from USD 0.29 billion in 2025 to USD 0.53 billion by 2032 at a 9.2% CAGR.

 

Histotripsy and Transplantation Extend the Treatable Boundary

Histotripsy introduces nonthermal mechanical tissue destruction. In October 2023, the FDA classified the Edison System as a Class II device for noninvasive destruction of liver tumors, including unresectable tumors, using focused ultrasound. Adoption will depend on equipment cost, treatment throughput, physician training, reimbursement and durable local-control evidence.

Radiation therapy accounted for 9.0% of the market and USD 0.23 billion in 2025 and is projected to reach USD 0.35 billion by 2032 at a 6.1% CAGR, with its share declining to 8.0%. Histotripsy may compete with percutaneous ablation and stereotactic radiation in selected patients while creating an option where probe placement is difficult.

Liver transplantation is developing for highly selected patients with unresectable, liver-limited colorectal metastases. In the TRANSMET study cited by the National Cancer Institute, five-year overall survival was 57% with chemotherapy plus transplantation compared with 13% with chemotherapy alone. Organ scarcity and strict biological selection will keep this pathway concentrated in transplant-oncology centers.

 

Competitive Landscape

Competition in the liver metastasis treatment market spans drugs, ablation systems, radioembolization products, implantable pumps, imaging tools, and noninvasive technologies, with companies increasingly offering integrated hospital-based treatment programs rather than standalone devices.

Key activity includes Boston Scientific’s May 2025 acquisition of Intera Oncology for about USD 172 million, expanding its hepatic artery infusion pump portfolio. Sirtex continues to compete with SIR-Spheres, supported by a September 2025 CE Mark expansion covering both primary and secondary liver tumors, while Boston Scientific’s TheraSphere remains focused on FDA-approved hepatocellular carcinoma use.

HistoSonics is emerging as a new category leader with its Edison histotripsy platform, a noninvasive tumor destruction technology. In pharmaceuticals, Amgen, Bristol Myers Squibb, and Pfizer are advancing mutation-targeted colorectal cancer therapies. Academic and research institutions still support early innovation but are expected to decline in share from 8.0% (USD 0.21 billion) in 2025 to 6.0% (USD 0.27 billion) by 2032.

 

Regional Market Analysis

North America

North America held 40.0% of the market and USD 1.04 billion in 2025. It is projected to reach USD 1.64 billion by 2032 at a 6.7% CAGR, while its share declines to 37.0%. Its position reflects high treatment intensity, FDA-approved targeted therapies, Medicare coverage and concentrated hepatobiliary expertise. The United States is projected to record 158,850 new colorectal cancer cases in 2026.

Europe

Europe accounted for 28.0% and USD 0.73 billion in 2025. It is projected to reach USD 1.19 billion by 2032 at a 7.3% CAGR, with a 27.0% share. IARC’s GLOBOCAN 2024 estimates identify 527,533 new colorectal cancer cases and 245,444 associated deaths in Europe. National registries, hepatobiliary audits and NICE governance support controlled adoption through specialist centers.

Asia-Pacific

Asia-Pacific represented 23.0% and USD 0.60 billion in 2025. It is projected to reach USD 1.24 billion by 2032, increasing its share to 28.0% at the fastest regional CAGR of 11.0%. IARC estimates that Asia recorded 1,064,396 new colorectal cancer cases and approximately 2.97 million five-year prevalent cases in 2024. Growth is strongest where interventional radiology, molecular testing, insurance and tertiary cancer infrastructure are expanding.

Latin America

Latin America accounted for 5.0% and USD 0.13 billion in 2025 and is projected to reach USD 0.22 billion by 2032 at a 7.9% CAGR, maintaining its share. Advanced liver surgery, molecular therapies and radioembolization remain concentrated in large urban hospitals and private oncology networks.

Middle East & Africa

The Middle East & Africa represented 4.0% and USD 0.10 billion in 2025. It is projected to reach USD 0.13 billion by 2032 at a 3.5% CAGR, reducing its share to 3.0%. The WHO reported in July 2026 that availability of the top 20 priority cancer medicines ranged from 9% to 54% in low- and lower-middle-income countries, compared with 68% to 94% in high-income countries, limiting adoption of multimodal care.

 

Analyst Perspective

The main constraint is not the absence of treatment options but the limited number of patients assessed while they remain eligible for liver-directed intervention. Delayed referral, extrahepatic progression, inadequate liver reserve and previous-treatment toxicity can remove patients from curative or conversion pathways.

Advanced management requires hepatobiliary surgeons, medical and radiation oncologists, interventional radiologists, nuclear-medicine teams, molecular laboratories and repeated multidisciplinary review. Market expansion will be strongest where health systems establish referral networks, complete molecular testing early and reconsider resectability after systemic response. Companies able to combine products with clinical training, treatment planning and hospital-program implementation will hold a stronger position than suppliers offering isolated drugs or devices.

 

Liver Metastasis Treatment Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026–2032
Market Size Value in 2025	USD 2.60 Billion
Revenue Forecast in 2032	USD 4.42 Billion
Overall Growth Rate	CAGR of 7.9% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019–2024
Unit	USD Million/Billion, CAGR (2026–2032)
Segmentation	By Treatment Type, By Primary Cancer Type, By End User, By Geography
By Treatment Type	Systemic Therapy [Chemotherapy, Targeted Therapy, Immunotherapy], Surgical Resection, Ablation Therapy [Radiofrequency Ablation, Microwave Ablation, Cryoablation], Embolization Therapy [Transarterial Chemoembolization, Radioembolization], Radiation Therapy, Hepatic Artery Infusion, Histotripsy, Liver Transplantation
By Primary Cancer Type	Colorectal Cancer, Breast Cancer, Lung Cancer, Pancreatic Cancer, Melanoma, Neuroendocrine Tumours, Other Cancers
By End User	Hospitals, Cancer Treatment Centers, Specialty Oncology Clinics, Ambulatory Surgical Centers, Academic and Research Institutions
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Rising incidence of cancers that commonly spread to the liver, expanding biomarker-guided systemic therapies, increasing use of ablation and arterial interventions, improved conversion of unresectable disease to surgery, and growing adoption of multidisciplinary liver-treatment programs
Customization Option	Available upon request